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Abstract
Purpose This study aimed to determine the proportion and
characteristics of radiation oncology outpatients who were
willing to answer questions about their life expectancy.
Methods A cross-sectional patient self-report survey was con-
ducted using touch screen computers in Australian radiation
oncology treatment centers. The primary outcome was the
respondent’s willingness to complete a survey subsection
about life expectancy. Demographic and disease characteristics
were also collected, and level of anxiety and depression was
assessed using the Hospital Anxiety and Depression Scale.
Results Of the 469 oncology outpatients who completed the
survey, 327 (70 %; 95 % CI, 65 %, 74 %) indicated that they
were willing to answer questions about life expectancy. Being
female (p<0.001), older (p<0.05), born in Asia (p<0.05), and
being diagnosed with cancer types other than breast and
prostate cancer (p<0.01) were associated with lower odds of
answering life expectancy questions.
Conclusions The opportunity to opt-out of survey questions
about sensitive issues such as life expectancy is a feasible
method for accessing important information about patient
preferences while minimizing burden. Further research may
be needed to improve acceptability of life expectancy research
to some patient groups.
Keywords Cancer . Patient-centered care . Patient
preference . Prognosis
Introduction
A cancer diagnosis is often associated with a reduced life
expectancy [1]. Therefore oncologists are often faced with the
intimidating task of communicating this bad news to patients
and their families [2]. Although communication training is
provided in medical schools, clinicians have reported feeling
inadequately trained in breaking bad news [3]. Variation in
individual patient preferences for life expectancy disclosure
compounds the complexity of this task for clinicians [3, 4].
Additionally, there is limited evidence about patient disease
and demographic characteristics associated with different pref-
erences [5]. Although guidelines based on consensus views
have been developed to assist clinicians with the task of life
expectancy disclosure [6, 7], it remains critical to build empir-
ical evidence about how different methods of disclosure impact
on patient psychosocial outcomes [2].
Although there is a need to build the evidence base regard-
ing prognostic communication [5], ethical concerns about the
potential burden of this research have been raised [8]. The
development of a patient-centered methodological approach
to assessing patients’ preferences for life expectancy disclosure
may prove successful for increasing representative research
output, while alsominimizing the burden of research to patients
in accordance with their preferences for involvement. This
approach involves embedding a set of optional life expectancy
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questions within a larger patient experience survey and giving
patients the chance to “opt-out” of these questions. It was
thought that this may help to minimize patient burden, while
also maximizing overall consent rates and representativeness
[9]. Importantly, this approach would also allow identification
of patient characteristics relating to a willingness to answer
these questions, helping to improve our understanding of
acceptability of the topic of life expectancy to different cancer
patient groups [5].
Aims and hypotheses
This research aimed to determine (1) the proportion of cancer
patients willing to answer survey questions about their life
expectancy, and (2) examine disease and demographic factors
associated with a willingness to answer these questions. We
expected that females would be more likely than males to
answer life expectancy questions, based on past findings
suggesting females want more detailed information about
cancer [10]. Based on previous research into cancer patients’
preferences for prognosis communication, it was expected that
patients perceiving a shorter survival time would be less likely
to complete life expectancy questions than those perceiving a
longer survival time [11]. Similarly, we expected that patients
reporting that their treatment had curative intent would be
more willing to complete the life expectancy questions than
those perceiving that their treatment was with palliative intent.
It has also been suggested that willingness to participate in
research trials may be linked to psychological distress; how-
ever, findings are mixed [2, 5, 12]. We expected that respond-
ents born in some Asian and European regions may be less
likely to complete life expectancy questions [4, 5], and that
younger respondents would be more willing to answer the life
expectancy questions [5, 11].
Patients and methods
Ethical standards
All human research was approved by the University of
Newcastle HREC and the New South Wales Population
and Health Services Research Ethics Committee. Research
governance authorization was also sought and obtained
from the participating hospitals.
Patients
Cancer outpatients were recruited from four metropolitan ra-
diation therapy treatment centers between February 2010 and
December 2010. The four treatment centers were attached to
large public teaching hospitals located in high socio-economic
status areas of Sydney, Australia. Patients were eligible for
inclusion if they were aged 18 years or older; had a cancer
diagnosis; were attending radiation therapy treatment as an
outpatient, and understood sufficient English to complete the
survey. Patients who were attending the clinic for the first time
were excluded.
Procedure
A research assistant (RA) approached patients waiting for
their radiation therapy treatment appointment. Participants
were provided with a written information statement about the
study. The RA explained that the survey contained questions
about quality of care, coping with cancer, and an optional
section about life expectancy. The RA then sought informed
consent from eligible patients after indicating that the patient
could choose not to complete the section on life expectancy.
Once informed consent was obtained, patients completed the
survey in the waiting room using a portable touch screen
computer. Digivey software (CREOSO Corporation, Phoe-
nix, Arizona) was used to program the survey, which was
administered using a Dell Latitude XT2 touch screen com-
puter. The use of touch screen computer surveys in oncology
settings has been previously found to be acceptable to cancer
patients [13].
Measures
The following modules were embedded within a larger
10–15-min survey:
Outcome measure
The primary outcome was patients’ willingness to complete
life expectancy questions. The introduction to this section of
the survey read “The following questions ask for your views
about your life expectancy. This will provide information
that may help to improve services for cancer patients.”
Participants were asked to indicate whether or not they were
willing to complete questions about their life expectancy by
either selecting “I am willing to complete this section of the
survey” or “Please skip to the next section of the survey”. If
participants initially chose to complete the life expectancy
section, but then changed their mind, they could use the
“BACK” navigation button on the survey screen to return to
the introductory screen for the life expectancy section. This
then allowed participants to skip the life expectancy section
and any previous responses were deleted.
Explanatory measures
Demographic and disease data on age, gender, diagnosis,
country of birth, time since diagnosis, number of outpatient
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appointments, number of oncology appointments, and
treatment aim were collected via the self-report survey.
The Hospital Anxiety and Depression Scale (HADS) was
used to assess anxiety and depression. The HADS con-
tains two seven-item subscales each producing a score
between 0 and 21 indicating normal (0–7), mild (8–10),
moderate (11–14), or severe (15–21) levels of anxiety,
and/or depression [14]. There is evidence that this mea-
sure is both reliable and valid in a cancer patient popula-
tion [15], and produces comparable results when it is
administered via paper and pencil or via touch screen
computers [16]. Although various thresholds have been
used in the literature to identify caseness [17], a subscale
score of 11 or more can be indicative of clinically signif-
icant levels of anxiety and/or depression [14]. This thresh-
old was used to classify respondents having clinically
significant depression or anxiety.
Statistical analysis
The proportion of participants willing to answer survey
questions about their life expectancy was estimated with a
95 % confidence interval. Disease and demographic factors
hypothesized as being associated with a willingness to an-
swer these questions were examined using univariate and
multiple logistic regression analyses. Because of small
numbers of rarer cancer types, the cancer type variable
was collapsed across low incidence categories to give the
following “breast,” “prostate”, and “other” for univariate
analysis. Variables of interest included: age category, sex,
region of birth, clinically significant anxiety, clinically sig-
nificant depression, cancer type, and perceived palliative
treatment aim. Variables with a p value of 0.2 or less for
univariate analysis were included in a multiple logistic
regression model, and the backward stepwise method was
used to remove variables with a p value of 0.1 or greater on
the likelihood ratio test. Odds ratios with 95 % confidence
intervals were calculated for univariate and multiple regres-
sion models and a significance level of 5 % was used.
Recruitment site (hospital) was included in the multiple
regression analysis to control for between site differences
in patient characteristics. Analyses were undertaken using
STATA version 11.2.
Sample size
This study aimed to recruit a total of 450 patients from four
hospital sites, which would allow us to obtain prevalence
estimates with 95 % CI’s with ±5 % of the point estimate.
This sample size would also allow us to detect differences of
15 % in characteristics between the groups who opt-in and
who opt-out of the life expectancy section with a 5 % signif-
icance level and 80 % power.
Results
Of the 785 patients screened for eligibility, 126 did not
meet the eligibility criteria. Of the 659 patients who
were invited to join the study, 570 (86 %) consented
to participate in the survey, of whom 82 % (n=469; 71
% of all eligible participants) completed the survey in
its entirety. Data was not available for participants who
consented but were unable to complete the survey due
to time limitations. Participants were 242 males and 227
females, with a mean age of 61.5 years (SD013.2,
median062.9; Q1, Q3, 52.4, 70.2). At the time of
recruitment, respondents were a mean of 85.8 weeks
since diagnosis (SD0169.1, median028.7; Q1, Q3,
16.2, 57.2), and had attended a mean of 11.6 outpatient
radiation therapy appointments (SD010.2, median09;
Q1, Q3, 4, 18). Respondents reported that their most
recent primary cancer diagnosis was breast (28 %),
prostate (22 %), head and neck (9.6 %), colorectal
(bowel; 5.3 %), brain (4.3 %), lung (4.0 %), melanoma
(3.4 %), non-Hodgkin’s lymphoma (3.2 %), other cancers
(17 %), and 2.1 % did not know. Sixty-nine percent of
respondents were Australian born.
Three hundred and twenty-seven (70 %, 95 % CI,
65 %, 74 %) of the 469 participants who completed the
survey indicated that they were willing to answer ques-
tions about life expectancy. Overall, this meant that
50 % of all eligible participants completed the survey
questions about life expectancy. Table 1 outlines the
results of the univariate and multiple logistic regression
analysis assessing characteristics associated with willing-
ness to complete the life expectancy questions. Following
univariate analysis, clinically significant anxiety (p00.3)
and perceived palliative treatment aim (p00.5) were
excluded from the model (see Table 1). Remaining
variables entered into the multiple logistic regression
analysis included age group, gender, cancer type, region
of birth, and depression. Compared to the youngest age
group (18–49 years) those aged 60–69 years and 70 years or
more had significantly lower odds of answering the life
expectancy questions (see Table 1). Females had signifi-
cantly lower odds of answering the life expectancy ques-
tions than males. Participants born in Asia had lower odds
of answering the life expectancy questions than Australian-
born participants, and a similar trend was seen for
European-born participants (although marginally non-
significant). Compared to participants with breast cancer,
participants with “other cancers” (i.e., not breast or prostate
cancer) had significantly lower odds of completing the life
expectancy questions. Having clinically significant depres-
sion according to the HADS was not found to be significantly
associated with the outcome of interest in the multiple regres-
sion model.
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Discussion
In the current study, 70 % of participants who completed
the survey (and 50 % of all eligible patients) were willing
to answer a subset of questions about their life expectan-
cy. Previous research into patients’ preferences for life
expectancy information has yielded similar consent rates.
A large USA-based interview study achieved a consent
rate of approximately 70 % when assessing the views of
638 advanced cancer patients (recruited from outpatient
clinics at seven hospital sites) about whether end of life
care discussions had occurred [18]. Australian survey re-
search into cancer patients’ prognostic communication
preferences have obtained consent rates of 61 % [19];
while interview/focus group studies with palliative care
patients have obtained consent rates of up to 83 % [20].
However, recruitment for these studies was conducted
through oncologists or palliative care services, and poor
Table 1 Univariate and multiple logistic regression of characteristics of 469 participants completing the patient views survey









Hospital 4.0 (3), p00.2663
Site 1 121 (70 %) 1 1
Site 2 90 (65 %) 0.8 (0.4–1.2) 0.8 (0.5–1.3)
Site 3 51 (68 %) 0.9 (0.5–1.6) 1.0 (0.5–1.9)
Site 4 65 (77 %) 1.4 (0.8–2.6) 1.5 (0.8–2.8)
Age group 10.7 (3), p00.0137
18–49 72 (77 %) 1 1
50–59 73 (72 %) 0.7 (0.4–1.4) 0.6 (0.3–1.3)
60–69 104 (68 %) 0.6 (0.3–1.1) 0.4 (0.2–0.8)
70+ 78 (64 %) 0.5 (0.3–1.0) 0.4 (0.2–0.7)
Sex 13.9 (1), p<0.0002
Male 179 (74 %) 1 1
Female 148 (65 %) 0.7 (0.4–1.0) 0.3 (0.2–0.6)
Region of birth 10.8 (4), p00.0291
Australia 237 (73 %) 1 1
UK and Ireland 26 (67 %) 0.7 (0.4–1.5) 0.7 (0.3–1.4)
Asia 19 (58 %) 0.5 (0.2–1.0) 0.4 (0.2–0.8)
Europe 20 (57 %) 0.5 (0.2–1.0) 0.5 (0.2–1.0)
Other 25 (66 %) 0.7 (0.3–1.4) 0.5 (0.2–1.1)
Palliative treatment aim
Yes 43 (73 %) 1
No 263 (69 %) 1.2 (0.7–2.2)
Cancer type 13.4 (2), p00.0012
Breast 99 (74 %) 1 1
Prostate 79 (75 %) 1 (0.6–1.9) 0.5 (0.2–1.1)
Othera 149 (65 %) 0.6 (0.4–1.0) 0.3 (0.2–0.6)
Clinically significant anxietyb
Yes 44 (58 %) 0.8 (0.4–1.3)
No 281 (70 %) 1
Clinically significant depressionb 1.0 (1), p00.3151c
Yes 15 (65 %) 0.6 (0.3–1.3)
No 310 (71 %) 1
Observations within each variable may not add to the total due to missing values
a Including brain, colorectal, head and neck, lung, non-Hodgkin’s lymphoma, and other cancer types
b Assessed using the Hospital Anxiety and Depression Scale
c Eliminated during backwards stepwise multiple logistic regression analysis
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consent rates among oncologists or community nurses
may have introduced response bias [19].
Our findings indicating that older participants had lower
odds than younger participants of answering questions about
life expectancy appear to be consistent with past research.
Kaplowitz and colleagues [11] found that older people were
significantly less likely to request and to be given prognosis
information. Similarly, a review by Fujimori and colleagues
reported that younger patients were more likely to express a
desire for more prognosis information than older patients
[5]. Younger patients may be more likely to have dependent
children and be willing to discuss life expectancy information
for planning purposes [21]. This may also reflect changes in
patient attitudes, preferences, and expectations over time
towards increased involvement in cancer treatment decision
making [22].
The increased willingness to answer questions on life
expectancy among males was contrary to our expectations.
It has been reported that women diagnosed with cancer are
more likely to want more detailed general information about
cancer than men [10]. A study of response rates to an
epidemiological survey involving 25,000 participants found
that consent to review medical records higher in males older
than 50 than females over 50 [23]. Other research has found
that men were significantly more likely to be given a quan-
titative life expectancy estimate than women [11]. Taken
together, these findings may suggest that males are more
likely to be willing to be involved in research about personal
or potentially sensitive issues than females.
Our findings showed that Australian-born participants had
higher odds of completing life expectancy questions than
respondents born in the Asian region, and marginally non-
significantly higher odds than those born in Europe. Previous
reports have indicated that culture may influence patients’
preferences for information about life expectancy prognosis
discussions [5]. A recent review of patients’ preferences for
life expectancy communication reported that studies con-
ducted in Asian countries have reported that fewer than
30 % of patients wish to know about life expectancy, while
approximately 60 % of Westerners do [4, 5]. Regional varia-
tions in physician views and practices surrounding disclosure
of palliative illness status in Europe, Latin America, and
Canada have also been reported [24]. These differences may
be related to beliefs about the potential impact that awareness
of a poor life expectancy estimate may have on patient hope,
and consequentially on outcomes. Therefore, the present find-
ings may be reflective of cultural attitudes towards discussion
of life expectancy. However, a recent qualitative study looking
at communication preferences in migrants to Australia with
Greek-, Arabic-, and Chinese-speaking backgrounds, suggests
that these migrant groups are possibly more likely than Anglo
Australian patients to prefer to have access to prognostic
information [25]. It may be that a willingness to answer
questions about life expectancy is not comparable to a patient
preference to have access to prognostic information. It is also
possible that responses regarding willingness to answer life
expectancy questions in the current study may have been
influenced by family members who may have been accompa-
nying them in the waiting room during survey completion.
Further exploration of discordance between patient and family
preferences may be warranted in Australian and international
settings. However, it does seems likely that some level of
cultural variation in patient preferences for answering life
expectancy questions exists and further exploration of how
this relates to patients preferences for life expectancy disclo-
sure may bewarranted. This is particularly pertinent given that
individuals without adequate English language to complete
the survey were excluded from this study. Future studies
should extend these findings to culturally and linguistically
diverse communities [25].
Prior research has indicated that patients who identified
themselves as having a shorter survival timemay be less likely
to want, request, and receive life expectancy information
compared to those perceiving longer survival time [11]. It
has also been suggested that an increased physical burden of
cancer may be associated with a preference to have less
involvement in cancer care decision making [10]. The current
study found no association between patients’ perceived treat-
ment aim and willingness to answer the life expectancy
questions. However, individuals in the present study diag-
nosed with cancers with high 5-year survival rates (i.e.,
breast or prostate) [1] were more willing than those with
other cancers to complete life expectancy questions. It is
possible that the greater willingness among breast and prostate
cancer patients was linked to perceived length of life. This
would appear consistent with the findings of Kaplowitz and
colleagues [11]. For instance, increased rates of distress in
some poorer prognosis cancer types such as of the lung and
brain have been suggested to be associated with feelings of
“doom” [26]. This finding warrants further exploration, as the
preferences of patients with less common cancers tend to be
under reported in current consensus guidelines.
Limitations
This research compared the characteristics of survey partici-
pants who were and were not willing to answer a subset of
questions about their life expectancy. However, as part of the
consent process potential participants were made aware of the
optional section about life expectancy, and potential respond-
ents (for whom demographic information is not available) may
have opted out at this point. Additionally, although the current
study achieved high consent rates to the initial survey (87 %),
only 70% of all eligible patients completed the entire survey in
the time available. Once again, demographic information is not
available for participants with incomplete surveys, meaning
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comparisons between survey completers and non-completers
are not possible. Given that 70 % of eligible participants
completed the survey in its entirety and 70% of these respond-
ents were willing to answer questions about their life expec-
tancy, overall, 50 % of all eligible participants completed the
life expectancy questions. Although this overall consent rate is
comparable to other research [27], it may limit the external
validity of the study results.
All patient demographic and disease data was collected
via patient self-report, meaning accuracy for some items
may be questioned [28]. Accuracy of self-reported cancer
history validated against medical records and cancer registry
data has been found to be high [29], with high sensitivity in
cancer outpatient samples [30].
Implications
There remains a need for high-quality research in the area of
life expectancy communication. However, this research needs
to minimize the risk of psychological distress to patients while
also maximizing the representativeness of samples consulted.
This approach to empowering patients to decide whether or
not to answer research questions of this nature, rather than
having access to patients restricted by clinical gatekeepers,
requires a balancing of the ethical principles of beneficence
and autonomy [31]. The current study found high consent
rates to both the initial survey and also to the life expectancy
questions embedded within the main survey, which resulted,
in an overall acceptable consent rate. This suggests that this
patient-centered approach to researching this sensitive topic
was both feasible and acceptable, but the degree of accept-
ability varied across different subgroups. Further researchmay
be needed to identify how to improve acceptability of this
research to subgroups including those who are female, aged
60 years or over, diagnosed with less common cancer types,
and Australian migrants from Asian regions [5, 22].
Conclusions
Giving cancer patients the opportunity to opt out of questions
about a sensitive issue is a feasible and acceptable option for
accessing important information about patient preferences.
This method also promotes greater autonomy than clinician-
determined methods of access to patients for these types of
surveys. Further researchmay be needed to identify approaches
to improve acceptability of research on life expectancy discus-
sions with cancer patients who are older, female, diagnosed
with less common cancer types, and who are born in Asia.
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